Signaling alterations caused by drugs and autophagy

被引:15
作者
Dent, Paul [1 ]
Booth, Laurence [1 ]
Poklepovic, Andrew [2 ]
Hancock, John F. [3 ]
机构
[1] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Dept Biochem & Med, Med Coll Virginia Campus, Richmond, VA 23298 USA
[3] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA
关键词
Autophagy; HDAC; Neratinib; Rubicon; RAS; Hippo; Chaperone; IONIZING-RADIATION; CARCINOMA-CELLS; IN-VITRO; H-RAS; ACTIVATION; INHIBITORS; RESISTANCE; SORAFENIB; INDUCTION; MELANOMA;
D O I
10.1016/j.cellsig.2019.109416
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Autophagy is an evolutionary conserved process that recycles cellular materials in times of nutrient restriction to maintain viability. In cancer therapeutics, the role of autophagy in response to multi-kinase inhibitors, alone or when combined with histone deacetylase (HDAC) inhibitors acts, generally, to facilitate the killing of tumor cells. Furthermore, the formation of autophagosomes and subsequent degradation of their contents can reduce the expression of HDAC proteins themselves as well as of other signaling regulatory molecules such as protein chaperones and mutated RAS proteins. Reduced levels of HDAC6 causes the acetylation and inactivation of heat shock protein 90, and, together with reduced expression of the chaperones HSP70 and GRP78, generates a strong endoplasmic reticulum (ER) stress response. Prolonged intense ER stress signaling causes tumor cell death. Reduced expression of HDACs 1, 2 and 3 causes the levels of programed death ligand 1 (PD-L1) to decline and the expression of Class I MHCA to increase which correlates with elevated immunogenicity of the tumor cells in vivo. This review will specifically focus on the downstream implications that result from autophagic-degradation of HDACs, RAS and protein chaperones.
引用
收藏
页数:8
相关论文
共 111 条
[1]   LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases [J].
Abe, Taiki ;
Umeki, Ikumi ;
Kanno, Shin-ichiro ;
Inoue, Shin-ichi ;
Niihori, Tetsuya ;
Aoki, Yoko .
CELL DEATH AND DIFFERENTIATION, 2020, 27 (03) :1023-1035
[2]   HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression [J].
Ahn, Mee-Young .
ONCOLOGY LETTERS, 2018, 16 (05) :6552-6560
[3]   Targeting Autophagy in Cancer: Recent Advances and Future Directions [J].
Amaravadi, Ravi K. ;
Kimmelman, Alec C. ;
Debnath, Jayanta .
CANCER DISCOVERY, 2019, 9 (09) :1167-1181
[4]   Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells [J].
Bareford, M. Danielle ;
Park, Margaret A. ;
Yacoub, Adly ;
Hamed, Hossein A. ;
Tang, Yong ;
Cruickshanks, Nichola ;
Eulitt, Patrick ;
Hubbard, Nisan ;
Tye, Gary ;
Burow, Matthew E. ;
Fisher, Paul B. ;
Moran, Richard G. ;
Nephew, Kenneth P. ;
Grant, Steven ;
Dent, Paul .
CANCER RESEARCH, 2011, 71 (14) :4955-4967
[5]   Structure, Function, and Regulation of the Hsp90 Machinery [J].
Biebl, Maximilian M. ;
Buchner, Johannes .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2019, 11 (09)
[6]   The Lethality of [Pazopanib plus HDAC Inhibitors] Is Enhanced by Neratinib [J].
Booth, Laurence ;
Roberts, Jane L. ;
Poklepovic, Andrew ;
Dent, Paul .
FRONTIERS IN ONCOLOGY, 2019, 9
[7]  
Booth Laurence, 2018, Oncol Signal, V1, P19, DOI 10.1016/j.onsig.2017.07.001
[8]   Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells [J].
Booth, Laurence ;
Roberts, Jane L. ;
Sander, Cindy ;
Lalani, Alshad S. ;
Kirkwood, John M. ;
Hancock, John F. ;
Poklepovic, Andrew ;
Dent, Paul .
CANCER BIOLOGY & THERAPY, 2019, 20 (05) :700-710
[9]   Neratinib augments the lethality of [regorafenib plus sildenafil] [J].
Booth, Laurence ;
Roberts, Jane L. ;
Rais, Rumeesa ;
Cutler, Richard E., Jr. ;
Diala, Irmina ;
Lalani, Alshad S. ;
Hancock, John F. ;
Poklepovic, Andrew ;
Dent, Paul .
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (04) :4874-4887
[10]  
Booth Laurence, 2018, Oncotarget, V9, P6062, DOI 10.18632/oncotarget.23681